GSK to Acquire Reliant

GlaxoSmithKline (GSK) has reached an agreement to acquire U.S.-based Reliant Pharmaceuticals for $1.65 billion.

Reliant focuses on cardiovascular therapies and recorded net sales of $341 million in the nine months ending Sept. 30, according to GSK.

Reliant’s portfolio includes U.S. rights to Lovaza (omega-3-acid ethyl esters), a treatment for adult patients with high triglyceride levels.

The acquisition is subject to approval by the FTC and is expected to conclude before the end of the year.